Skip to main content
Fig. 3 | Critical Care

Fig. 3

From: ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock

Fig. 3

Biomolecular RAS profile according to ACEi and ARB exposure status. A–D Baseline renin, Ang-I, Ang-II, and Ang-I/Ang-II ratio according to ACEi and ARB medication exposure. Y-axes are on log2-scale. Bars indicate median, boxes IQR, whiskers data range. Dots represent individual patients. Δ indicates the difference in geometric mean between the indicated group, bracketed values the 95% CI. E Change in log-renin at hour 3 in angiotensin-II versus placebo treated patients, stratified by ACEi and ARB exposure status. Lower-level Δ and bracketed values reflect the difference and 95% CI from the unadjusted linear model, as above, for angiotensin-II versus placebo treatment within the ACEi/ARB exposure group. Upper-level Δ and bracketed values reflect the same, but for the interaction effect of treatment with ACEi/ARB medication group. The pRx shows the p-value for the effect of angiotensin-II versus placebo treatment in the no ACEi/ARB group. The pint. reflects the p-value for the interaction effect of ACEi or ARB exposure with angiotensin-II treatment, where pint. < 0.05 indicates a significantly different effect of treatment versus ACEi/ARB unexposed patients. ang angiotensin, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker

Back to article page

Critical Care

ISSN: 1364-8535